B. Riley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $14 from $17 and keeps a Neutral rating on the shares following the Q1 report. The firm says the company faces significant competition from Padcev -plus pembro in bladder cancer, and a shift toward novel pipeline programs appears unlikely based on current activity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics price target lowered to $22 from $26 at Citizens JMP
- Bicycle Therapeutics Reports Q1 2025 Progress and Financials
- Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
- Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating
- Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating